Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
Stopped early · Phase 2
Conditions studied: SCN8A Developmental and Epileptic Encephalopathy Syndrome
In brief
Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
Key facts
- Study ID
- NCT05226780
- Run by
- Neurocrine Biosciences
- People needed
- 8
- Starts
- 2022-07-12
- Expected to finish
- 2025-11-12
- Last updated by the study team
- 2026-05-27
Who can join
Age: 2 and older, up to 22. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Medical Center — San Francisco, California, United States
- Children's National Hospital — Washington D.C., District of Columbia, United States
- University of Rochester — Rochester, New York, United States
- Cook Children's Medical Center — Fort Worth, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.